Inhibikase Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $ |
Gross Profit | -6 | -6 | -6 |
EBITDA | -5,043 | -4,775 | -4,396 |
EBIT | -5,050 | -4,782 | -4,403 |
Net Income | -4,959 | -4,649 | -4,177 |
Net Change In Cash | 0 | 0 | |
Free Cash Flow | -5,054 | -3,867 | -3,428 |
Cash | 3,086 | 2,353 | 9,165 |
Basic Shares | 7,535 | 6,340 | 6,186 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $260 | $123 | $3,100 | $698 |
Gross Profit | -13,357 | 116 | 3,100 | 698 |
EBITDA | -19,912 | -18,121 | -14,766 | -2,818 |
EBIT | -20,089 | -18,128 | -14,766 | -2,818 |
Net Income | -19,028 | -17,905 | -14,805 | -2,877 |
Net Change In Cash | 260 | 123 | 3,100 | 698 |
Free Cash Flow | -18,099 | -17,594 | -14,297 | -1,129 |
Cash | 9,165 | 7,188 | 40,750 | 13,953 |
Basic Shares | 5,333 | 4,201 | 3,034 | 1,675 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.65 |
2024-06-30 | -$0.66 |
2024-03-31 | -$0.73 |
2023-12-31 | -$0.64 |
